Management Team - Expertise in Stem Cell Biology, Biomedical Engineering, Medicine, and Start-up Management
AmnioChor has assembled a team of executives who have the appropriate backgrounds to aggressively execute the Company’s development and commercialization strategy.
Russ Schweizer, Chief Executive Officer and Chief Operations Officer
A senior corporate executive focused on company leadership and growth by innovation over the past three decades, and specializing in leading companies through the commercialization of new technologies. Educated as an engineer, and trained for business management, Mr. Schweizer has lead integrated design, marketing, and manufacturing teams in creating over $1 Billion of sustainable revenue for companies in the medical device, and consumer product fields. Today he serves as Chief Executive Officer and Chief Operations Officer in building AmnioChor, a biotech startup, by securing an equity investment base and executing the creation and commercialization of AmnioChor’s new products, processes and regulatory compliances.
Dale Woodbury, PhD, Co-Founder & Chief Science Officer
Dr. Woodbury will build AmnioChor’s Scientific Research Team and direct the Company’s Preclinical Studies. He has 30 years of experience in laboratory research focused on gene expression and stem cell biology. He has published a dozen papers on Mesenchymal Stem Cell biology and is an inventor on 6 patent applications and three issued patents. Dr. Woodbury received his BS from the University of Connecticut in Pathobiology and his PhD in Microbiology and Molecular Genetics from Rutgers University.
Akiva Marcus, MD, PhD, Co-Founder & Chief Medical Officer
Dr. Marcus will be AmnioChor's primary liaison to the Pharma/Biotech industry, determining the most advantageous preclinical research and securing related licensing partners. Dr. Marcus is a practicing physician with expertise in Stem Cell Biology and Regenerative Medicine. He has published numerous papers on stem cell biology in major scientific journals and currently performs research in this nascent field. Dr. Marcus received his MD from the University of Medicine and Dentistry of New Jersey - Robert Wood Johnson Medical School (RWJMS) and PhD in Neuroscience and Stem Cell Biology jointly from RWJMS and Rutgers University.
Ari Perl, MD (’13), MBA (’15), Associate
Mr. Perl works with AmnioChor’s management team to strategically execute the Company’s business plan. He is a fourth-year medical student at the NYU School of Medicine and plans to pursue a MBA from Columbia Business School. Previously, Mr. Perl was employed as an analyst in the Business Development and Strategy Group at Credit Suisse Alternative Investments, where he worked directly with executive management to conduct due diligence on over 50 new business opportunities, strategic initiatives, and M&A across a wide array of industries. He graduated Summa Cum Laude from Yeshiva University with a BA in economics and a concentration in pre-health sciences.
Scientific Advisory Board
AmnioChor’s Stem Cell technology has been recognized as innovative by experts in fetal medicine and stem cell cryopreservation. These medical leaders have agreed to join the Company’s Scientific Advisory Board, and are valuable insight and guidance with regards to the Company’s progress and planning. The Company expects to expand its Advisory Board in the coming year.
Venkateswara Rao Karuparthy, M.D.
Dr Karuparthy MD is board certified anesthesiologist and double board certified interventional pain management specialist. He is also certified in medical acupuncture and certified practitioner of Ayurveda & Yoga. He is a published researcher and trained in multiple alternative modalities of yoga, Ayurveda and acupuncture for effective integration. After serving as faculty at Indiana University school of Medicine and University of Iowa carver school of medicine, he founded “Integrative pain centers of America Inc.,” with a unique integration that delivers superior outcomes. Dr Karupathy is in the area pain medicine, regenerative medicine and rejuvenation healthcare space for more than 25 years. He has been practicing Regenerative medicine technologies like PRP (Platelet Rich Plasma,) Bone marrow derived Mesenchymal stem cells for chronic pain conditions since 2005. He wants to bring leading edge technologies of prevention, health wellness and treatment to people who need most, especially the “elderly”. He want to seamlessly integrate clinical medicine with Alternative techniques with Zero side effects and Zero complications both in short term and long term creating “Home of Health & Rejuvenation.
John Smulian, MD, MPH
Dr. Smulian is the Director of the Division of Maternal Fetal Medicine in the Department of Obstetrics and Gynecology at Lehigh Valley Hospital in Allentown, PA. He is Board Certified in Obstetrics and Gynecology as well as in Maternal-Fetal Medicine. His specialties include perinatal epidemiology; maternal and child health; diseases of mother and fetus; and prenatal diagnosis/birth defects. He earned his MD at Tulane University School of Medicine and his MPH at Tulane University School of Public Health and Tropical Medicine, both in 1985.
Douglas Fugman, PhD
Dr. Fugman is the Managing Director of the Rutgers University Cell and DNA repository. He has expertise in the design, construction, and operation of industry scale cryopreservation facilities. Dr. Fugman oversees the processing, cataloguing, and cryopreservation of biological samples received from across the globe at the nation’s largest repository. Dr. Fugman received his PhD from the University of Cincinnati.
AmnioChor Board of Directors
The Company is currently in the process of formulating a board comprised of capabilities and minds for today’s startup business, and tomorrow’s biotech products.